Results from Planned Interim Analysis Expected First Quarter 2023 A Positive Outcome in RESILIENT Together with Results from Previous Positive Phase 3 Study RELIEF May Support Submission of an NDA Get our FREE Newsletter! Discover … Continue reading Tonix Pharmaceuticals (NASDAQ: TNXP) Initiates Enrollment in the RESILIENT Study, a Potentially Pivotal Phase 3 Study of TNX-102 SL for the Management of Fibromyalgia